Focus: Danaher is a diversified conglomerate with a major diagnostics business segment, operating at massive scale with 50,000+ employees and $23.9B in FY2025 revenue. As a public company (NYSE: DHR), it leverages the Danaher Business System to drive operational excellence across diagnostics, life sciences, and environmental solutions.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Danaher to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Danaher
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Danaher's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
8-K Filing: ESAB Corp (ESAB) (CIK 0001877322) — ESAB CORPORATION PRESS RELEASE, DATED APRIL 2, 2026
ESAB CORPORATION PRESS RELEASE, DATED APRIL 2, 2026
8-K Filing: INTEST CORP (INTT) (CIK 0001036262) — EX-99.1
EX-99.1
8-K Filing: NOV Inc. (NOV) (CIK 0001021860) — EX-99.1
EX-99.1
8-K Filing: DANAHER CORP /DE/ (DHR) (CIK 0000313616) — EX-99.1
EX-99.1
8-K Filing: MASIMO CORP (MASI) (CIK 0000937556) — EXHIBIT 99.1
EXHIBIT 99.1
8-K Filing: EXACT SCIENCES CORP (EXAS) (CIK 0001124140) — 8-K
8-K
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Community-based "X-ray+Xpert® MTB/RIF ultra pooling test" case-finding strategy among high-risk groups in rural areas: a prospective application study.
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo